Zanidatamab
August 24, 2022
Future Medicine
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Zanidatamab
June 30, 2022
ESMO World GI Congress
HERIZON-GEA-01: A Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in First-line Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced/metastatic Gastroesophageal Adenocarcinoma (GEA)
Tabernero et al.
Zanidatamab
June 6, 2022
ASCO
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Preliminary results from a Phase 1b/2 study
Zanidatamab
June 4, 2022
ASCO
Zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma: Preliminary results from a Phase 1b/2 study
Preclinical
May 2, 2022 - May 6, 2022
PEGS
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
Petersen et al.
Zanidatamab
April 10, 2021
AACR
Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action
Abraham et al.
Preclinical
March 31, 2022
World ADC London
TOPO1i ADC Platform: From Concept to Pipeline
Zanidatamab
December 8, 2021
SABCS
Zanidatamab (ZW25), a HER2-targeted Bispecific Antibody, in Combination with Chemotherapy (chemo) for HER2-positive Breast Cancer (BC): Results from a Phase 1 Trial
Bedard et al.
Zanidatamab
September 15, 2021
ESMO
Phase (Ph) 2 Study of Zanidatamab + Chemotherapy (chemo) in First Line (1L) HER2 expressing Gastroesophageal Adenocarcinoma (GEA)
Ku et al.
Zanidatamab
December 8, 2021
SABCS
Zanidatamab in Combination with Evorpacept in Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-expressing Cancers, Including Breast Cancer: a Phase 1b/2, Multicenter, Open-Label, Dose-Finding and Cohort-Expansion Study (ZWI-ZW25-204)
Hurvitz et al.
Preclinical
April 10, 2021
AACR
Increasing the therapeutic index of IL-12 by engineering for tumor-specific protease activation
Bishop et al.
Zanidatamab
April 10, 2021
AACR
The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers
Weisser et al.
